Edition:
United States

Neuralstem Inc (CUR.OQ)

CUR.OQ on NASDAQ Stock Exchange Capital Market

1.83USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$1.83
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
203,680
52-wk High
$6.58
52-wk Low
$0.89

Latest Key Developments (Source: Significant Developments)

Neuralstem Q3 loss per share $0.01
Monday, 13 Nov 2017 07:30am EST 

Nov 13 (Reuters) - Neuralstem Inc :Neuralstem reports third quarter 2017 fiscal results and provides clinical and business update.Q3 loss per share $0.01.Neuralstem - ‍expect to provide detailed update on corporate strategy after post-phase 2 meeting with fda in h1 2018​.Neuralstem Inc - ‍ recent financing further extended co's cash runway to sufficiently support continued research on NSI-189 and to support operations​.Neuralstem Inc - ‍plans to meet with U.S. Food and Drug Administration in first half of 2018 to discuss clinical development path for NSI-189​.  Full Article

Neuralstem Inc gets two additional U.S. patents
Thursday, 7 Sep 2017 07:03am EDT 

Sept 7 (Reuters) - Neuralstem Inc :Neuralstem Inc - ‍been awarded two additional patents by United States Patent and Trademark Office​.  Full Article

Neuralstem reports Q2 loss per share $0.39
Tuesday, 8 Aug 2017 07:30am EDT 

Aug 8 (Reuters) - Neuralstem Inc :Neuralstem reports second quarter 2017 fiscal results and provides clinical and business update.Q2 loss per share $0.39.  Full Article

‍CVI investments reports a 8.3 pct passive stake in Neuralstem
Monday, 7 Aug 2017 10:46am EDT 

Aug 7 (Reuters) - Neuralstem Inc :‍CVI Investments reports a 8.3 percent passive stake in Neuralstem Inc as of July 27, 2017 - SEC filing.  Full Article

Neuralstem announces top-line phase 2 data of nsi-189 for major depressive disorder
Tuesday, 25 Jul 2017 08:15am EDT 

July 25 (Reuters) - Neuralstem Inc ::Neuralstem announces top-line phase 2 data of nsi-189 for major depressive disorder.Neuralstem Inc - ‍study did not meet its primary efficacy endpoint​.Neuralstem Inc - 40 mg qd dose was directionally positive on madrs​.Both 40 mg QD and 40 MG bid doses of NSI-189 were well-tolerated in study with no serious adverse events reported.Neuralstem Inc - ‍results were also directionally positive on hamilton depression rating scale (ham-d17) at both doses​.Neuralstem - ‍of two secondary efficacy endpoints analyzed so far, patient-rated SDQ achieved statistical significance with NSI-189 40 MG QD​.  Full Article

Neuralstem files for mixed shelf of up to $100 mln
Thursday, 8 Jun 2017 05:11pm EDT 

June 8 (Reuters) - Neuralstem Inc ::Neuralstem Inc files for mixed shelf of up to $100 million -sec filing.  Full Article

Neuralstem reports last subject out in phase 2 trial of NSI-189 for major depressive disorder
Wednesday, 17 May 2017 04:05pm EDT 

May 17 (Reuters) - Neuralstem Inc :Neuralstem reports last subject out in phase 2 trial of NSI-189 for major depressive disorder.  Full Article

Neuralstem reports Q1 loss per share $0.68
Wednesday, 10 May 2017 04:05pm EDT 

May 10 (Reuters) - Neuralstem Inc :Neuralstem reports first quarter 2017 fiscal results provides clinical and business update.Q1 loss per share $0.68.Neuralstem - Expect existing cash, cash equivalents and short-term investments will fund anticipated level of operations into second half of 2018.  Full Article

Neuralstem says CFO leaves company
Thursday, 4 May 2017 04:02pm EDT 

May 4 (Reuters) - Neuralstem Inc :Neuralstem - on april 30, Jonathan Lloyd Jones, chief financial officer of Neuralstem, Inc. Left company to pursue other opportunities - sec filing.Neuralstem Inc - Richard Daly will serve as company's principal financial and accounting officer, on an interim basis.  Full Article

Neuralstem expands phase 1 safety trial of NSI-566 neural stem cells in spinal injury
Wednesday, 12 Apr 2017 07:35am EDT 

Neuralstem Inc : Neuralstem expands phase 1 safety trial of NSI-566 neural stem cells in spinal injury . Neuralstem - New cohort of four patients will be added to ongoing phase 1 human clinical trial for NSI-566 spinal cord-derived neural stem cells .Neuralstem - Amended protocol was approved by U.S. Food and Drug Administration, institutional review board at study site, University of California San Diego.  Full Article

BRIEF-Neuralstem Q3 loss per share $0.01

* Neuralstem reports third quarter 2017 fiscal results and provides clinical and business update